Clinical trials: Hepatitis C
Chronic Hepatitis C
Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection
The purpose of this study is to evaluate the antiviral efficacy, safety, tolerability of combination therapy with sofosbuvir (SOF) containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT01826981
- Testing
- LDV/SOF, SOF, RBV
- Where
- 2 sites in New Zealand
- Volunteers
- 359 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- REACH (NCT02582671)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Volunteers
- 101 people
- Sponsor
- AbbVie
Chronic Hepatitis C Infection
Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)
This study will evaluate the hepatic (liver) and plasma pharmacokinetics of Vaniprevir (MK-7009) by evaluation of ribonucleic acid (RNA) of the hepatitis C virus (HCV) in genotype 1, HCV-infected participants.
- Trial name
- NCT00954993
- Testing
- Vaniprevir
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Pharmacokinetics
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the patients and is often…
- Trial name
- NCT00947349
- Testing
- ribavirin (RBV), pegylated interferon (PegIFN) alfa-2a, BI 201335 NA high
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Chronic HCV Infection
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + ribavirin (RBV) in treatment-naive adults with chronic genotype 1 or 3 hepatitis C virus (HCV) infection.
- Trial name
- NCT02074514
- Testing
- Sofosbuvir, RBV
- Where
- 13 sites in India
- Volunteers
- 117 people
- Sponsor
- Gilead Sciences
HIV-1 Infection, Hepatitis C
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir.
- Trial name
- NCT02605304
- Testing
- Ledipasvir/sofosbuvir, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis…
- Trial name
- NCT03020004
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 70 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis C
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C.
- Trial name
- NCT00686517
- Testing
- Pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with…
- Trial name
- COPE-HCV (NCT00919633)
- Testing
- interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Depression
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
Primary end points incidence of depression defined as a Montgomery Asberg Depression Scale Score (MADRS) of 13 or higher during antiviral therapy (up to 48 weeks, depending on genotype) effect of an antidepressive pre-treatment…
- Trial name
- CIPPAD (NCT00136318)
- Testing
- Escitalopram, Peginterferon alfa-2a, Ribavirin
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Charite University, Berlin, Germany
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered…
- Trial name
- NCT04382404
- Testing
- Sofosbuvir-Velpatasvir Drug Combination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Catherine Anne Chappell
Chronic Hepatitis C, Genotype 1
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin…
- Trial name
- HCV RWE (NCT02669940)
- Volunteers
- 158 people
- Sponsor
- AbbVie
Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
- Trial name
- NCT00781274
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C, Chronic Kidney Disease
Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
- Trial name
- NCT02503735
- Testing
- Sofosbuvir/Ledipasvir FDC
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Chronic Hepatitis C
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- AMBER (NCT02581189)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Volunteers
- 565 people
- Sponsor
- AbbVie
Hepatitis C Infection, HIV
HCV-HIV Co-infected Patient Cohort in Thailand
This is a study of HCV treatment using the standard regimen of pegylated-interferon plus ribavirin in HIV co-infected patients participating in the PHPT cohort study.
- Trial name
- NCT02247440
- Testing
- Peg-interferon + ribavirin under HIV physician supervision
- Where
- 5 sites in Thailand
- Volunteers
- 18 people
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C Virus Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
This primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with chronic…
- Trial name
- NCT02378935
- Testing
- VOX, SOF/VEL, RBV
- Where
- 34 sites in United States, New Zealand and 1 more
- Volunteers
- 205 people
- Sponsor
- Gilead Sciences
HIV, Hepatitis C
A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
The CTSI-PLACE Study is a study for men and women with HIV/hepatitis C co-infection or HIV only. The study looks at the impact of having hepatitis C virus in addition to HIV on risk for cardiovascular disease.
- Trial name
- CTSI-PLACE (NCT02597790)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of California, Los Angeles
Cirrhosis, Chronic Hepatitis C
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
Background: Some people who have chronic hepatitis C do not respond to the usual treatment with peginterferon and ribavirin. New chronic hepatitis treatments are being developed that may work better for different people.
- Conditions
- Cirrhosis, Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT01888900
- Testing
- DUAL, QUAD
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Depression, Hepatitis C
Improving Quality of Life for Veterans Undergoing Interferon Treatment
The purpose of this study is to evaluate a group psychotherapy intervention and a telehealth intervention for veterans undergoing interferon treatment for the hepatitis C virus.
- Trial name
- NCT00117559
- Testing
- Telehealth Treatment
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- US Department of Veterans Affairs